Donanemab provides clinical benefits but is unlikely to be cost-effective under current Australian thresholds. Policymakers should balance economic evidence with unmet need, equity considerations and healthcare sustainability when making reimbursement decisions. Further research using real-world evidence and disaggregated analyses by geography and socioeconomic status is warranted.
Building similarity graph...
Analyzing shared references across papers
Loading...
Gao et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69eb0bfa553a5433e34b5740 — DOI: https://doi.org/10.5694/mja2.70186
Lan Gao
Rosie Watson
Nawaf Yassi
The Medical Journal of Australia
Deakin University
The Royal Melbourne Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...